Cutaneous melanoma: some current considerations
Keywords:
cutaneous melanoma, skin neoplasia, oncological institutions.Abstract
The cutaneous melanoma is a severe and potentially mortal disease that affects the population of the whole world and that is conditioned by many risk factors related to some lifestyles that can be modified. The opportune and early finding of this clinical entity elevates the survival of affected people and it favors the therapeutic result; however, it is not diagnosed on time occasionally. At present it is already presented in younger individuals with 25-29 years old and with great probability of generating metastasis, which constitutes a concern in the health field. In this respect, it was decided to make this literature review, with the purpose of to update some elements on the topic and to make them known in the national and foreign medical community.
Downloads
Download data is not yet available.
References
1. Oliveria S, Saraiya M, Geller A, Heneghan M, Jorgensen C. Sun exposure and risk of melanoma. Arch Dis Child. 2006; 91(2): 131–8.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5-29.
3. MINSAL. Unidad de Vigilancia de Enfermedades no transmisibles y Estudios, Departamento de Epidemiología, División de Planificación Sanitaria Subsecretaría de Salud Pública. Primer Informe de Registros Poblacionales de Cáncer de Chile, quinquenio 2003-2007. Santiago de Chile: MINSAL; 2012.
4. Kraft Rovere R, Pires ME. Melanoma patterns of distant relapse: a study of 108 cases from a South Brazilian center. An Bras Dermatol. 2016; 91(1): 40-3.
5. Lucas R, McMichael T, Smith W, Armstrong B. Solar ultraviolet radiation: Global burden of disease from solar ultraviolet radiation. Ginebra: OMS; 2006. (Environmental Burden of Disease Series No. 13)
6. Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic classification of cutaneous melanoma. Cell. 2015; 161: 1681-96.
7. Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, et al. Melanoma, Version 4. 2014. JNCCN. 2014; 12: 621-911.
8. Sondak VK, Gibney GT. Surgical management of melanoma. Hematol Oncol Clin North Am. 2014; 28(3): 455-70.
9. Martins da Silva VP, Kida Ikino J, Mazzochi Sen M, Holthausen Nunes D, di Guinta G. Dermoscopic features of thin melanomas: A comparative study of melanoma in situ and invasive melanomas smaller than or equal to 1 mm. An Bras Dermatol. 2013; 88: 712-7.
10. Gao L, van den Hurk K, Moerkerk PTM, Goeman JJ, Beck S, Gruis NA, et al. Promoter CpG Island Hyper methylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy. J Invest Dermatol. 2014; 134: 2957-66.
11. Pinheiro P. Melanoma–cáncer de piel. MD.Saúde. 2018 [citado 28/10/2018]. Disponible en: https://www.mdsaude.com/es/2015/12/melanoma.html
12. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
13. Ciudad Blanco C, Avilés Izquierdo JA, Lázaro Ochaita P, Suárez Fernández R. Dermoscopic findings for the early detection of melanoma: Analysis of 200 cases. Actas Dermosifiliogr. 2014; 105: 683-93.
14. Solís Arias MP, Lammoglia Ordiales L, Toussaint Caire S, Galván Martínez I, Fonte Ávalos V. Multiple primary melanoma: a clinical case and review of the literature. ] Gac Med Mex. 2014; 150: 101-5.
15. Sordo C, Gutiérrez C. Cáncer de piel y radiación solar: experiencia peruana en la prevención y detección temprana del cáncer de piel y mela¬noma. Rev Peru Med Exp Salud Publica. 2013; 30(1): 113-7.
16. Rigel D, Friedman RJ, Kopf AW, Weltman R, Prioleau P, Safai B, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol Surg Oncol. 1991; 17: 44-8.
17. Registro Nacional de Melanoma Cutáneo. Características del tumor en el momento del diagnóstico: 15 años de experiencia. Actas Dermo-Sifiliográficas. 2013; 104(9): 789-99.
18. Pramio DT, Kashiwabara AY, Pennacchi PC, Rivas MP, Maria-Engler SS, Antônio HJ, et al. Epigenetic signature of differentially methylated genes in cutaneous melanoma. Applied Cancer Research. 2017; 37: 34.
19. Dial WF. ABCD rule aids in preoperative diagnosis of malignant melanoma. Cosmetic Dermatol. 1995; 8(3): 32-4.
20. Liu D, Liu X, Xing M. Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma. Biochem Biophys Res Commun. 2012; 425: 45–50.
21. Goodson AG, Grossman D. Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol. 2009; 60: 719-35.
22. Hernández C, Ruiz A, Reigosa A, Maldonado G, Parada D, Ball E, et al. Reunión de consenso en melanoma maligno. Revista Venezolana de Oncología. 2005 [citado 28/10/2018]; 17(1). Disponible en: http://www.scielo.org.ve/scielo.php?script=sci_arttext&pid=S0798-05822005000100011
23. Reed D, Kudchadkar R, Zager JS, Sondak VK, Messina JL. Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Cancer Netw. 2013; 11: 679-86.
24. George E, McClain SE, Slingluff CL, Polissar NL, Patterson JW, Colombino M, et al. Discrepant alterations in main candidate genes among multiple primary melanomas. J Transl Med. 2014; 12: 117.
25. Solís-Arias MP, Lammoglia Ordiales L, Toussaint-Caire S, Galván Martínez I, Fonte Ávalos V. Multiple primary melanoma: a clinical case and review of the literature. Gac Med Mex. 2014; 150: 101-5.
26. Grobb JJ, Bonerandi JJ. The ugly duckling sing: Identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 1998; 134: 103-4.
27. Linertová R, Valcárcel-Nazco C, Lacalle-Remigio JR. Tratamiento quirúrgico de lesiones melanocíticas benignas para la prevención del melanoma. Medicina Clínica (English Edition). 2016; 147(4): 162-70.
28. Grotz TE, Glorioso JM, Pockaj BA, Harmsen WS, Jakub JW. Preservation of the deep muscular fascia and locoregional control in melanoma. Surgery. 2013; 53: 535-41.
29. Ayala Cortés AS, Garza Rodríguez V, Ocampo Candiani J. Actualidades en tratamiento del melanoma en etapas avanzadas. Gaceta Médica de México. 2014; 150 Suppl 2: 145-55.
30. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: ACC; 2014.
31. Shah DJ, Dronca RS. Latest advances in chemotherapeutic targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc. 2014; 89(4): 504-19.
32. Rodríguez R, et al. Terapias actuales en melanoma metastásico. Rev Med Chile. 2016; 144: 1448-58.
33. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res. 2013; 19(5): 1009-20.
34. Two-Year Survival and Safety Update in Patients (pts) with Treatment-Naïve Advanced Melanoma (MEL) Receiving Nivolumab (NIVO) or Dacarbazine (DTIC) in Check Mate-066. Actas de Society for Melanoma Research 2015 International Congress; 18-21 Nov 2015; San Francisco: Society for Melanoma Research; 2015.
35. Giudice G, Leuzzi S, Robusto F, Ronghi V, Nacchiero E, Giar-dinelli G, et al. Sentinel lymph node biopsy in head and neck melanoma. G Chir. 2014; 35: 149-55.
36. Strom T, Caudell JJ, Han D, Zager JS, Yu D, Cruse CW, et al. Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer. 2014; 120(9): 1369-78.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5-29.
3. MINSAL. Unidad de Vigilancia de Enfermedades no transmisibles y Estudios, Departamento de Epidemiología, División de Planificación Sanitaria Subsecretaría de Salud Pública. Primer Informe de Registros Poblacionales de Cáncer de Chile, quinquenio 2003-2007. Santiago de Chile: MINSAL; 2012.
4. Kraft Rovere R, Pires ME. Melanoma patterns of distant relapse: a study of 108 cases from a South Brazilian center. An Bras Dermatol. 2016; 91(1): 40-3.
5. Lucas R, McMichael T, Smith W, Armstrong B. Solar ultraviolet radiation: Global burden of disease from solar ultraviolet radiation. Ginebra: OMS; 2006. (Environmental Burden of Disease Series No. 13)
6. Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic classification of cutaneous melanoma. Cell. 2015; 161: 1681-96.
7. Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, et al. Melanoma, Version 4. 2014. JNCCN. 2014; 12: 621-911.
8. Sondak VK, Gibney GT. Surgical management of melanoma. Hematol Oncol Clin North Am. 2014; 28(3): 455-70.
9. Martins da Silva VP, Kida Ikino J, Mazzochi Sen M, Holthausen Nunes D, di Guinta G. Dermoscopic features of thin melanomas: A comparative study of melanoma in situ and invasive melanomas smaller than or equal to 1 mm. An Bras Dermatol. 2013; 88: 712-7.
10. Gao L, van den Hurk K, Moerkerk PTM, Goeman JJ, Beck S, Gruis NA, et al. Promoter CpG Island Hyper methylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy. J Invest Dermatol. 2014; 134: 2957-66.
11. Pinheiro P. Melanoma–cáncer de piel. MD.Saúde. 2018 [citado 28/10/2018]. Disponible en: https://www.mdsaude.com/es/2015/12/melanoma.html
12. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
13. Ciudad Blanco C, Avilés Izquierdo JA, Lázaro Ochaita P, Suárez Fernández R. Dermoscopic findings for the early detection of melanoma: Analysis of 200 cases. Actas Dermosifiliogr. 2014; 105: 683-93.
14. Solís Arias MP, Lammoglia Ordiales L, Toussaint Caire S, Galván Martínez I, Fonte Ávalos V. Multiple primary melanoma: a clinical case and review of the literature. ] Gac Med Mex. 2014; 150: 101-5.
15. Sordo C, Gutiérrez C. Cáncer de piel y radiación solar: experiencia peruana en la prevención y detección temprana del cáncer de piel y mela¬noma. Rev Peru Med Exp Salud Publica. 2013; 30(1): 113-7.
16. Rigel D, Friedman RJ, Kopf AW, Weltman R, Prioleau P, Safai B, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol Surg Oncol. 1991; 17: 44-8.
17. Registro Nacional de Melanoma Cutáneo. Características del tumor en el momento del diagnóstico: 15 años de experiencia. Actas Dermo-Sifiliográficas. 2013; 104(9): 789-99.
18. Pramio DT, Kashiwabara AY, Pennacchi PC, Rivas MP, Maria-Engler SS, Antônio HJ, et al. Epigenetic signature of differentially methylated genes in cutaneous melanoma. Applied Cancer Research. 2017; 37: 34.
19. Dial WF. ABCD rule aids in preoperative diagnosis of malignant melanoma. Cosmetic Dermatol. 1995; 8(3): 32-4.
20. Liu D, Liu X, Xing M. Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma. Biochem Biophys Res Commun. 2012; 425: 45–50.
21. Goodson AG, Grossman D. Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol. 2009; 60: 719-35.
22. Hernández C, Ruiz A, Reigosa A, Maldonado G, Parada D, Ball E, et al. Reunión de consenso en melanoma maligno. Revista Venezolana de Oncología. 2005 [citado 28/10/2018]; 17(1). Disponible en: http://www.scielo.org.ve/scielo.php?script=sci_arttext&pid=S0798-05822005000100011
23. Reed D, Kudchadkar R, Zager JS, Sondak VK, Messina JL. Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Cancer Netw. 2013; 11: 679-86.
24. George E, McClain SE, Slingluff CL, Polissar NL, Patterson JW, Colombino M, et al. Discrepant alterations in main candidate genes among multiple primary melanomas. J Transl Med. 2014; 12: 117.
25. Solís-Arias MP, Lammoglia Ordiales L, Toussaint-Caire S, Galván Martínez I, Fonte Ávalos V. Multiple primary melanoma: a clinical case and review of the literature. Gac Med Mex. 2014; 150: 101-5.
26. Grobb JJ, Bonerandi JJ. The ugly duckling sing: Identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 1998; 134: 103-4.
27. Linertová R, Valcárcel-Nazco C, Lacalle-Remigio JR. Tratamiento quirúrgico de lesiones melanocíticas benignas para la prevención del melanoma. Medicina Clínica (English Edition). 2016; 147(4): 162-70.
28. Grotz TE, Glorioso JM, Pockaj BA, Harmsen WS, Jakub JW. Preservation of the deep muscular fascia and locoregional control in melanoma. Surgery. 2013; 53: 535-41.
29. Ayala Cortés AS, Garza Rodríguez V, Ocampo Candiani J. Actualidades en tratamiento del melanoma en etapas avanzadas. Gaceta Médica de México. 2014; 150 Suppl 2: 145-55.
30. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: ACC; 2014.
31. Shah DJ, Dronca RS. Latest advances in chemotherapeutic targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc. 2014; 89(4): 504-19.
32. Rodríguez R, et al. Terapias actuales en melanoma metastásico. Rev Med Chile. 2016; 144: 1448-58.
33. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res. 2013; 19(5): 1009-20.
34. Two-Year Survival and Safety Update in Patients (pts) with Treatment-Naïve Advanced Melanoma (MEL) Receiving Nivolumab (NIVO) or Dacarbazine (DTIC) in Check Mate-066. Actas de Society for Melanoma Research 2015 International Congress; 18-21 Nov 2015; San Francisco: Society for Melanoma Research; 2015.
35. Giudice G, Leuzzi S, Robusto F, Ronghi V, Nacchiero E, Giar-dinelli G, et al. Sentinel lymph node biopsy in head and neck melanoma. G Chir. 2014; 35: 149-55.
36. Strom T, Caudell JJ, Han D, Zager JS, Yu D, Cruse CW, et al. Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer. 2014; 120(9): 1369-78.
Published
2019-02-11
How to Cite
1.
Infante Carbonell MC, González Calzadilla ME, Jaén Infante L, del Valle Piñera S. Cutaneous melanoma: some current considerations. MEDISAN [Internet]. 2019 Feb. 11 [cited 2025 Jun. 4];23(1). Available from: https://medisan.sld.cu/index.php/san/article/view/2409
Issue
Section
Review articles
License
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
Guidelines for authors
